Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : AMIGOS INVITATIONAL YEEHAW PORTFOLIO -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (629)	7/7/1999 11:24:00 PM
From: Street Walker	Respond to of 1316

GUMM is conducting a multi University Study on Zicam Results will be published in a scientific journal later this fall. The I-cam receptor in the nasal cavity has been known for a long time, as you pointed out. Finally, we have Zicam that blocks the receptor, and hence the cold virus. The study should be complete next month. GUMM labled their product as a homeopathic so they wouldn't have to wait years for FDA approval. Its on the shelves now, and and people are buying it. There will be a major advertisment campaign throughout the cold season and will be advertised heavily in weekly store ads. Zicam will become the number 1 cold remedy in the $3 Billion market in years to come because of those "testimonials" to family, friends, and co-workers. Who has been accumulating shares of GUMM? Doctors, Pharmacists, Engineers, among others. I have high respect for "Ancient Pillroller" over on yahoo boards. He is a seasoned pharmacist and am glad he has joined in for the long term. Another pharmacist had so many sales that when it came to the initial order for this fall, he ordered 40X more Zicam than was recommended. GUMM is a position Trade. The float is being accumulated by people with a lot of money. There are not that many shares out there to buy. So when it starts going up, it will move fast. S.W.